We Pull An Enormous Amount Of Public Drug Data.
This Is Where We Play With It.
HelloPharmacist runs on public data. Every week our pipelines ingest the openFDA NDC Directory, FDA drug labels and adverse-event reports, CMS Medicaid utilization and HCPCS files, NIH and NLM references like RxNorm and the Dietary Supplement Label Database, FDA shortage and recall feeds, and more. That's the raw material behind our drug pages, interaction checkers, and lookup tools.
The Data Lab isn't something you need in order to use the site. It's a side room. We love data, and this is where we put pieces of it on display: interactive, explorable, and occasionally surprising. Expect it to grow.
Pick a dashboard
Three so far, each interactive. Choose where to start — you can switch any time from up here.
Dashboard: CMS State Drug Utilization Data
Medicaid & The Anti-Obesity GLP-1s
Semaglutide, tirzepatide, and liraglutide are each sold under separate brand names for obesity and for diabetes, so only NDC-level data can isolate the anti-obesity brands (Wegovy, Zepbound, Saxenda) from their diabetes siblings (Ozempic, Mounjaro, Victoza). CMS publishes Medicaid utilization by NDC, and this is what it shows, 2021 through 2025 (plus the first partial 2026 quarter).
Every dollar figure is gross (pre-rebate) reimbursement. Medicaid rebates on these drugs are large and confidential, so gross is a ceiling on real state cost, not an estimate of it.The Quarterly Curve
Totals by brand and quarter (summed over jurisdiction rows; pick a state in the filter row to drill down). The two markers are the 2024 label expansions: uses that fall outside Medicaid's optional weight-loss exclusion. (The Q4 2025 Wegovy dip is mostly one state's coverage pause, and 2026 Q1 is a partial file; see the notes under the charts.)
View as table
| Quarter | Wegovy rx | Wegovy gross | Zepbound rx | Zepbound gross | Saxenda rx | Saxenda gross | Liraglutide 3 mg (generic) rx | Liraglutide 3 mg (generic) gross |
|---|---|---|---|---|---|---|---|---|
| 2021 Q1 | - | - | - | - | 3,345 | $4,077,258 | - | - |
| 2021 Q2 | 0 | $0 | - | - | 4,095 | $5,035,870 | - | - |
| 2021 Q3 | 292 | $365,747 | - | - | 5,174 | $6,356,841 | - | - |
| 2021 Q4 | 2,018 | $2,336,444 | - | - | 5,525 | $6,568,258 | - | - |
| 2022 Q1 | 5,885 | $7,623,188 | - | - | 5,920 | $6,880,746 | - | - |
| 2022 Q2 | 9,229 | $12,184,335 | - | - | 11,606 | $14,236,901 | - | - |
| 2022 Q3 | 7,714 | $10,494,183 | - | - | 21,783 | $26,928,322 | - | - |
| 2022 Q4 | 7,348 | $10,113,704 | - | - | 28,528 | $34,950,871 | - | - |
| 2023 Q1 | 58,533 | $77,107,077 | - | - | 33,764 | $41,538,941 | - | - |
| 2023 Q2 | 125,826 | $164,609,518 | - | - | 30,432 | $36,909,072 | - | - |
| 2023 Q3 | 121,999 | $161,835,667 | - | - | 30,770 | $36,152,910 | - | - |
| 2023 Q4 | 101,191 | $133,300,075 | 429 | $417,217 | 11,829 | $14,198,888 | - | - |
| 2024 Q1 | 121,248 | $157,454,653 | 22,415 | $22,971,584 | 5,667 | $6,634,731 | - | - |
| 2024 Q2 | 207,454 | $268,508,349 | 43,384 | $44,353,664 | 8,145 | $9,664,957 | - | - |
| 2024 Q3 | 376,857 | $489,258,007 | 77,764 | $79,854,977 | 10,021 | $12,063,050 | - | - |
| 2024 Q4 | 397,258 | $513,971,661 | 134,592 | $137,054,726 | 9,939 | $11,852,643 | - | - |
| 2025 Q1 | 441,885 | $574,195,537 | 241,065 | $250,748,478 | 9,077 | $10,773,778 | - | - |
| 2025 Q2 | 471,038 | $613,598,485 | 340,696 | $355,901,693 | 7,656 | $9,082,919 | - | - |
| 2025 Q3 | 593,864 | $777,091,413 | 531,415 | $558,690,284 | 7,186 | $8,567,263 | 469 | $457,846 |
| 2025 Q4 | 487,096 | $633,526,067 | 608,430 | $640,228,737 | 4,888 | $5,794,396 | 1,222 | $1,154,269 |
| 2026 Q1 | 236,826 | $306,304,585 | 365,721 | $383,953,303 | 2,808 | $3,274,961 | 1,139 | $1,036,002 |
The 2025 Map: Where The Dollars Went
Each tile is a jurisdiction, shaded by 2025 totals (log-decade bins; the spread runs from thousands to billions). Hover or focus a tile for details.
View as table (all 52 jurisdictions)
| # | Jurisdiction | 2025 prescriptions | 2025 gross | Largest brand |
|---|---|---|---|---|
| 1 | CA | 1,712,999 | $2,070,189,885 | Wegovy |
| 2 | PA | 456,306 | $553,540,978 | Wegovy |
| 3 | MI | 359,264 | $422,922,581 | Wegovy |
| 4 | NC | 228,314 | $301,977,547 | Wegovy |
| 5 | MA | 217,409 | $227,531,574 | Zepbound |
| 6 | WI | 177,292 | $206,338,859 | Zepbound |
| 7 | MN | 124,839 | $154,245,439 | Wegovy |
| 8 | MO | 125,872 | $133,072,984 | Zepbound |
| 9 | VA | 45,599 | $54,288,304 | Wegovy |
| 10 | TN | 40,762 | $49,908,199 | Wegovy |
| 11 | MS | 32,253 | $42,513,687 | Wegovy |
| 12 | KS | 33,148 | $36,164,463 | Zepbound |
| 13 | NH | 19,738 | $23,103,899 | Wegovy |
| 14 | PR | 20,255 | $22,766,974 | Zepbound |
| 15 | RI | 12,749 | $15,166,208 | Wegovy |
| 16 | CO | 14,249 | $14,950,406 | Wegovy |
| 17 | SC | 11,352 | $14,077,600 | Wegovy |
| 18 | OH | 10,848 | $13,478,537 | Wegovy |
| 19 | NJ | 10,214 | $11,982,030 | Zepbound |
| 20 | IN | 8,749 | $10,060,111 | Zepbound |
| 21 | IA | 6,083 | $6,713,910 | Zepbound |
| 22 | CT | 5,475 | $6,636,744 | Zepbound |
| 23 | TX | 4,986 | $6,400,572 | Wegovy |
| 24 | OR | 4,607 | $5,138,703 | Zepbound |
| 25 | WA | 3,462 | $3,980,554 | Zepbound |
| 26 | IL | 3,046 | $3,485,913 | Zepbound |
| 27 | MD | 3,049 | $3,438,593 | Zepbound |
| 28 | KY | 3,257 | $3,329,239 | Zepbound |
| 29 | LA | 2,184 | $2,813,820 | Wegovy |
| 30 | ID | 2,293 | $2,583,910 | Zepbound |
| 31 | ME | 1,760 | $2,097,408 | Wegovy |
| 32 | GA | 1,530 | $2,080,658 | Wegovy |
| 33 | AL | 1,471 | $1,707,604 | Zepbound |
| 34 | NV | 1,240 | $1,497,915 | Wegovy |
| 35 | FL | 1,166 | $1,447,153 | Wegovy |
| 36 | AK | 1,305 | $1,378,946 | Zepbound |
| 37 | VT | 1,200 | $1,210,888 | Zepbound |
| 38 | AZ | 865 | $1,117,409 | Wegovy |
| 39 | OK | 622 | $872,568 | Wegovy |
| 40 | DE | 31,647 | $729,035 | Wegovy |
| 41 | NE | 471 | $526,528 | Zepbound |
| 42 | DC | 538 | $436,250 | Zepbound |
| 43 | HI | 244 | $364,647 | Wegovy |
| 44 | WV | 307 | $344,929 | Zepbound |
| 45 | NY | 208 | $302,969 | Wegovy |
| 46 | AR | 185 | $242,960 | Wegovy |
| 47 | MT | 189 | $239,077 | Wegovy |
| 48 | UT | 127 | $148,845 | Zepbound |
| 49 | WY | 139 | $144,167 | Zepbound |
| 50 | NM | 120 | $118,983 | Wegovy |
| 51 | ND | 0 | $0 | Wegovy |
| 52 | SD | 0 | $0 | Wegovy |
How Many Jurisdictions Report Any Use
Anti-obesity coverage is optional for state Medicaid programs, yet the number of jurisdictions with any reported utilization climbed steeply around the 2024 cardiovascular (Wegovy) and sleep-apnea (Zepbound) indications.
View as table
| Quarter | Wegovy | Zepbound | Saxenda | Liraglutide 3 mg (generic) |
|---|---|---|---|---|
| 2021 Q1 | - | - | 11 | - |
| 2021 Q2 | - | - | 13 | - |
| 2021 Q3 | 5 | - | 15 | - |
| 2021 Q4 | 7 | - | 15 | - |
| 2022 Q1 | 12 | - | 15 | - |
| 2022 Q2 | 13 | - | 16 | - |
| 2022 Q3 | 12 | - | 16 | - |
| 2022 Q4 | 13 | - | 17 | - |
| 2023 Q1 | 16 | - | 17 | - |
| 2023 Q2 | 17 | - | 17 | - |
| 2023 Q3 | 17 | - | 17 | - |
| 2023 Q4 | 17 | 8 | 14 | - |
| 2024 Q1 | 18 | 13 | 15 | - |
| 2024 Q2 | 27 | 15 | 16 | - |
| 2024 Q3 | 34 | 18 | 16 | - |
| 2024 Q4 | 41 | 20 | 16 | - |
| 2025 Q1 | 45 | 30 | 15 | - |
| 2025 Q2 | 47 | 38 | 15 | - |
| 2025 Q3 | 45 | 42 | 15 | 6 |
| 2025 Q4 | 47 | 44 | 9 | 12 |
| 2026 Q1 | 49 | 45 | 7 | 14 |
When States Turn Coverage On And Off
Anti-obesity drugs are an optional Medicaid benefit, and late 2025 into 2026 brought a wave of reversals. These verified policy changes explain much of the state-level movement in the charts above (pick the state in the filter row to see it). Coverage for the cardiovascular (Wegovy) and sleep-apnea (Zepbound) indications generally continued, which is why utilization rarely falls all the way to zero.
- North Carolina: covered obesity GLP-1s from Aug 1, 2024; paused Oct 1, 2025 during the budget stalemate, then reinstated Dec 12, 2025. The pause and rebound are unmistakable in NC's quarterly curve.
- South Carolina: became the 14th state to cover on Nov 1, 2024 (Wegovy preferred), then removed obesity coverage from its preferred drug list effective Jan 1, 2026 (P&T committee minutes, Nov 5, 2025); diabetes GLP-1s and Wegovy's cardiovascular/MASH uses continue.
- California: Medi-Cal, the class's largest spender, eliminated weight-loss GLP-1 coverage effective Jan 1, 2026 under the 2025-26 state budget (Medi-Cal Rx alert, Oct 21, 2025); Wegovy stays available by prior authorization for cardiovascular disease and MASH, Zepbound for sleep apnea, and under-21 coverage continues.
- Pennsylvania: covered since Jan 2023; ended adult (21+) weight-loss coverage effective Jan 1, 2026 (DHS bulletin, Nov 24, 2025; projected savings of $348M in FY 2025-26); under-21 access continues through EPSDT.
- New Hampshire: ended weight-loss-only coverage effective Jan 1, 2026 (DHHS notice, Oct 9, 2025); diabetes, cardiovascular, sleep-apnea, and MASH uses continue.
- Michigan: covering obesity drugs since Feb 1, 2022; from Jan 1, 2026 restricted to patients with morbid obesity who failed other interventions, as an alternative to bariatric surgery (MDHHS letter L 25-73).
- Coming later in 2026: Massachusetts ends weight-loss coverage Jul 3, 2026 (MassHealth Pharmacy Facts 271; cardiovascular, MASH, and sleep-apnea uses keep coverage), and Rhode Island restricts to type 2 diabetes only from Oct 1, 2026 under its FY2027 budget.
Also worth knowing: Connecticut has required a type 2 diabetes diagnosis on GLP-1 claims since Jan 15, 2025 and implemented its obesity-drug mandate with non-GLP-1 medications, and West Virginia's much-reported 2024 pilot pause was the state employee plan, not Medicaid. Verified against state Medicaid bulletins, preferred drug lists, and committee minutes, with KFF for the national count (16 covering states in Oct 2025, 13 as of Jan 2026).
Down To The Raw Grain: Utilization By NDC
Every package NDC in the cohort: total prescriptions and gross reimbursement for the whole window (2021 through the partial 2026 file), with a per-state breakdown on click. Non-suppressed rows only; national XX rows excluded. Sort by any column. NDCs tagged delisted no longer appear in the current openFDA NDC Directory; their utilization was recovered from SDUD claims history (manufacturers retire package codes over time).
| NDC | Brand | Package | Prescriptions | Gross | 2025 gross | States | |
|---|---|---|---|---|---|---|---|
| ▶ | 00169-4524-14 | Wegovy | 4 SYRINGE, PLASTIC in 1 CARTON (0169-4524-14) / .75 mL in 1 SYRINGE, PLASTIC (0169-4524-01) | 1,046,543 | $1,377,715,201 | $719,330,893 | 48 |
| ▶ | 00169-4525-14 | Wegovy | 4 SYRINGE, PLASTIC in 1 CARTON (0169-4525-14) / .5 mL in 1 SYRINGE, PLASTIC (0169-4525-01) | 761,224 | $984,107,814 | $480,031,298 | 49 |
| ▶ | 00169-4505-14 | Wegovy | 4 SYRINGE, PLASTIC in 1 CARTON (0169-4505-14) / .5 mL in 1 SYRINGE, PLASTIC (0169-4505-01) | 685,057 | $887,342,895 | $487,301,644 | 50 |
| ▶ | 00169-4501-14 | Wegovy | 4 SYRINGE, PLASTIC in 1 CARTON (0169-4501-14) / .5 mL in 1 SYRINGE, PLASTIC (0169-4501-01) | 649,083 | $841,963,273 | $476,478,436 | 49 |
| ▶ | 00169-4517-14 | Wegovy | 4 SYRINGE, PLASTIC in 1 CARTON (0169-4517-14) / .5 mL in 1 SYRINGE, PLASTIC (0169-4517-01) | 630,717 | $821,506,944 | $435,269,230 | 47 |
| ▶ | 00002-2495-80 | Zepbound | 4 SYRINGE in 1 CARTON (0002-2495-80) / .5 mL in 1 SYRINGE (0002-2495-01) | 620,339 | $648,355,720 | $473,009,668 | 49 |
| ▶ | 00002-2506-80 | Zepbound | 4 SYRINGE in 1 CARTON (0002-2506-80) / .5 mL in 1 SYRINGE (0002-2506-01) | 568,273 | $592,059,900 | $423,192,114 | 49 |
| ▶ | 00002-2484-80 | Zepbound | 4 SYRINGE in 1 CARTON (0002-2484-80) / .5 mL in 1 SYRINGE (0002-2484-01) | 431,719 | $451,443,956 | $334,517,344 | 44 |
| ▶ | 00002-2471-80 | Zepbound | 4 SYRINGE in 1 CARTON (0002-2471-80) / .5 mL in 1 SYRINGE (0002-2471-01) | 335,140 | $351,070,182 | $258,374,830 | 45 |
| ▶ | 00169-2800-15 | Saxenda | 5 SYRINGE, PLASTIC in 1 CARTON (0169-2800-15) / 3 mL in 1 SYRINGE, PLASTIC | 258,158 | $311,543,575 | $34,218,356 | 24 |
| ▶ | 00002-2457-80 | Zepbound | 4 SYRINGE in 1 CARTON (0002-2457-80) / .5 mL in 1 SYRINGE (0002-2457-01) | 231,953 | $244,453,106 | $177,646,938 | 39 |
| ▶ | 00002-2460-80 | Zepbound | 4 SYRINGE in 1 CARTON (0002-2460-80) / .5 mL in 1 SYRINGE (0002-2460-01) | 177,768 | $185,993,457 | $138,070,779 | 39 |
| ▶ | 00480-7250-46 | Liraglutide 3 mg (generic) | 5 SYRINGE, PLASTIC in 1 CARTON (0480-7250-46) / 3 mL in 1 SYRINGE, PLASTIC | 2,815 | $2,632,563 | $1,612,115 | 15 |
| ▶ | 00169-4415-31 | Wegovy | 30 TABLET in 1 BOTTLE, PLASTIC (0169-4415-31) | 751 | $993,326 | - | 14 |
| ▶ | 00002-2495-01 | Zepbounddelisted | Recovered from SDUD (delisted from the current NDC directory) | 234 | $258,625 | $258,625 | 2 |
| ▶ | 00002-2506-01 | Zepbounddelisted | Recovered from SDUD (delisted from the current NDC directory) | 224 | $249,941 | $224,189 | 2 |
| ▶ | 00169-4404-31 | Wegovy | 30 TABLET in 1 BOTTLE, PLASTIC (0169-4404-31) | 174 | $233,155 | - | 4 |
| ▶ | 00002-2484-01 | Zepbounddelisted | Recovered from SDUD (delisted from the current NDC directory) | 148 | $165,662 | $165,662 | 2 |
| ▶ | 00002-2471-01 | Zepbounddelisted | Recovered from SDUD (delisted from the current NDC directory) | 87 | $97,061 | $81,989 | 2 |
| ▶ | 00169-4409-31 | Wegovy | 30 TABLET in 1 BOTTLE, PLASTIC (0169-4409-31) | 12 | $16,086 | - | 1 |
| ▶ | 69097-0910-55 | Liraglutide 3 mg (generic) | 5 SYRINGE, PLASTIC in 1 CARTON (69097-910-55) / 3 mL in 1 SYRINGE, PLASTIC | 15 | $15,553 | - | 1 |
| ▶ | 00002-2460-01 | Zepbounddelisted | Recovered from SDUD (delisted from the current NDC directory) | 15 | $15,487 | $15,487 | 1 |
| ▶ | 00002-2457-01 | Zepbounddelisted | Recovered from SDUD (delisted from the current NDC directory) | 11 | $11,567 | $11,567 | 1 |
| ▶ | 00002-4178-31 | Foundayo | 1 BOTTLE in 1 CARTON (0002-4178-31) / 30 TABLET, FILM COATED in 1 BOTTLE (0002-4178-01) | 0 | $0 | - | 0 |
| ▶ | 00002-4178-62 | Foundayo | 1 BOTTLE in 1 CARTON (0002-4178-62) / 30 TABLET, FILM COATED in 1 BOTTLE | 0 | $0 | - | 0 |
| ▶ | 00002-4503-31 | Foundayo | 1 BOTTLE in 1 CARTON (0002-4503-31) / 30 TABLET, FILM COATED in 1 BOTTLE (0002-4503-01) | 0 | $0 | - | 0 |
| ▶ | 00002-4794-31 | Foundayo | 1 BOTTLE in 1 CARTON (0002-4794-31) / 30 TABLET, FILM COATED in 1 BOTTLE (0002-4794-01) | 0 | $0 | - | 0 |
| ▶ | 00002-4803-31 | Foundayo | 1 BOTTLE in 1 CARTON (0002-4803-31) / 30 TABLET, FILM COATED in 1 BOTTLE (0002-4803-01) | 0 | $0 | - | 0 |
| ▶ | 00002-4839-31 | Foundayo | 1 BOTTLE in 1 CARTON (0002-4839-31) / 30 TABLET, FILM COATED in 1 BOTTLE (0002-4839-01) | 0 | $0 | - | 0 |
| ▶ | 00002-4953-31 | Foundayo | 1 BOTTLE in 1 CARTON (0002-4953-31) / 30 TABLET, FILM COATED in 1 BOTTLE (0002-4953-01) | 0 | $0 | - | 0 |
| ▶ | 69097-0910-68 | Liraglutide 3 mg (generic) | 3 SYRINGE, PLASTIC in 1 CARTON (69097-910-68) / 3 mL in 1 SYRINGE, PLASTIC | 0 | $0 | - | 0 |
| ▶ | 00169-2800-90 | Saxenda | 1 SYRINGE, PLASTIC in 1 CARTON (0169-2800-90) / 3 mL in 1 SYRINGE, PLASTIC | 0 | $0 | - | 0 |
| ▶ | 00169-2800-97 | Saxenda | 1 SYRINGE, PLASTIC in 1 CARTON (0169-2800-97) / 3 mL in 1 SYRINGE, PLASTIC | 0 | $0 | - | 0 |
| ▶ | 50090-4257-00 | Saxenda | 5 SYRINGE, PLASTIC in 1 CARTON (50090-4257-0) / 3 mL in 1 SYRINGE, PLASTIC | 0 | $0 | - | 0 |
| ▶ | 00169-4415-92 | Wegovy | 30 TABLET in 1 BOTTLE, PLASTIC (0169-4415-92) | 0 | $0 | - | 0 |
| ▶ | 00169-4425-31 | Wegovy | 30 TABLET in 1 BOTTLE, PLASTIC (0169-4425-31) | 0 | $0 | - | 0 |
| ▶ | 00169-4501-01 | Wegovydelisted | Recovered from SDUD (delisted from the current NDC directory) | 0 | $0 | - | 0 |
| ▶ | 00169-4505-01 | Wegovydelisted | Recovered from SDUD (delisted from the current NDC directory) | 0 | $0 | - | 0 |
| ▶ | 00169-4517-01 | Wegovydelisted | Recovered from SDUD (delisted from the current NDC directory) | 0 | $0 | - | 0 |
| ▶ | 00169-4524-01 | Wegovydelisted | Recovered from SDUD (delisted from the current NDC directory) | 0 | $0 | - | 0 |
| ▶ | 00169-4525-01 | Wegovydelisted | Recovered from SDUD (delisted from the current NDC directory) | 0 | $0 | - | 0 |
| ▶ | 00169-4525-94 | Wegovy | 4 SYRINGE, PLASTIC in 1 CARTON (0169-4525-94) / .5 mL in 1 SYRINGE, PLASTIC (0169-4525-90) | 0 | $0 | - | 0 |
| ▶ | 00169-4572-14 | Wegovy | 4 SYRINGE, PLASTIC in 1 CARTON (0169-4572-14) / .75 mL in 1 SYRINGE, PLASTIC (0169-4572-01) | 0 | $0 | - | 0 |
| ▶ | 50090-5824-00 | Wegovy | 4 SYRINGE, PLASTIC in 1 CARTON (50090-5824-0) / .5 mL in 1 SYRINGE, PLASTIC | 0 | $0 | - | 0 |
| ▶ | 00002-0152-01 | Zepbound | 1 VIAL, SINGLE-DOSE in 1 CARTON (0002-0152-01) / .5 mL in 1 VIAL, SINGLE-DOSE | 0 | $0 | - | 0 |
| ▶ | 00002-0152-04 | Zepbound | 4 VIAL, SINGLE-DOSE in 1 CARTON (0002-0152-04) / .5 mL in 1 VIAL, SINGLE-DOSE | 0 | $0 | - | 0 |
| ▶ | 00002-0152-61 | Zepbound | 4 VIAL, SINGLE-DOSE in 1 CARTON (0002-0152-61) / .5 mL in 1 VIAL, SINGLE-DOSE | 0 | $0 | - | 0 |
| ▶ | 00002-0243-01 | Zepbound | 1 VIAL, SINGLE-DOSE in 1 CARTON (0002-0243-01) / .5 mL in 1 VIAL, SINGLE-DOSE | 0 | $0 | - | 0 |
| ▶ | 00002-0243-04 | Zepbound | 4 VIAL, SINGLE-DOSE in 1 CARTON (0002-0243-04) / .5 mL in 1 VIAL, SINGLE-DOSE | 0 | $0 | - | 0 |
| ▶ | 00002-1214-01 | Zepbound | 1 VIAL, SINGLE-DOSE in 1 CARTON (0002-1214-01) / .5 mL in 1 VIAL, SINGLE-DOSE | 0 | $0 | - | 0 |
| ▶ | 00002-1214-04 | Zepbound | 4 VIAL, SINGLE-DOSE in 1 CARTON (0002-1214-04) / .5 mL in 1 VIAL, SINGLE-DOSE | 0 | $0 | - | 0 |
| ▶ | 00002-1340-01 | Zepbound | 1 VIAL, SINGLE-DOSE in 1 CARTON (0002-1340-01) / .5 mL in 1 VIAL, SINGLE-DOSE | 0 | $0 | - | 0 |
| ▶ | 00002-1340-04 | Zepbound | 4 VIAL, SINGLE-DOSE in 1 CARTON (0002-1340-04) / .5 mL in 1 VIAL, SINGLE-DOSE | 0 | $0 | - | 0 |
| ▶ | 00002-1423-01 | Zepbound | 1 VIAL, SINGLE-DOSE in 1 CARTON (0002-1423-01) / .5 mL in 1 VIAL, SINGLE-DOSE | 0 | $0 | - | 0 |
| ▶ | 00002-1423-04 | Zepbound | 4 VIAL, SINGLE-DOSE in 1 CARTON (0002-1423-04) / .5 mL in 1 VIAL, SINGLE-DOSE | 0 | $0 | - | 0 |
| ▶ | 00002-2002-01 | Zepbound | 1 VIAL, SINGLE-DOSE in 1 CARTON (0002-2002-01) / .5 mL in 1 VIAL, SINGLE-DOSE | 0 | $0 | - | 0 |
| ▶ | 00002-2002-04 | Zepbound | 4 VIAL, SINGLE-DOSE in 1 CARTON (0002-2002-04) / .5 mL in 1 VIAL, SINGLE-DOSE | 0 | $0 | - | 0 |
| ▶ | 00002-2506-61 | Zepbound | 4 SYRINGE in 1 CARTON (0002-2506-61) / .5 mL in 1 SYRINGE | 0 | $0 | - | 0 |
| ▶ | 00002-3511-11 | Zepbound | 1 SYRINGE in 1 CARTON (0002-3511-11) / 2.4 mL in 1 SYRINGE (0002-3511-01) | 0 | $0 | - | 0 |
| ▶ | 00002-3522-11 | Zepbound | 1 SYRINGE in 1 CARTON (0002-3522-11) / 2.4 mL in 1 SYRINGE (0002-3522-01) | 0 | $0 | - | 0 |
| ▶ | 00002-3533-11 | Zepbound | 1 SYRINGE in 1 CARTON (0002-3533-11) / 2.4 mL in 1 SYRINGE (0002-3533-01) | 0 | $0 | - | 0 |
| ▶ | 00002-3544-11 | Zepbound | 1 SYRINGE in 1 CARTON (0002-3544-11) / 2.4 mL in 1 SYRINGE (0002-3544-01) | 0 | $0 | - | 0 |
| ▶ | 00002-3555-01 | Zepbounddelisted | Recovered from SDUD (delisted from the current NDC directory) | 0 | $0 | - | 0 |
| ▶ | 00002-3555-11 | Zepbound | 1 SYRINGE in 1 CARTON (0002-3555-11) / 2.4 mL in 1 SYRINGE (0002-3555-01) | 0 | $0 | - | 0 |
| ▶ | 00002-3566-11 | Zepbound | 1 SYRINGE in 1 CARTON (0002-3566-11) / 2.4 mL in 1 SYRINGE (0002-3566-01) | 0 | $0 | - | 0 |
| ▶ | 00002-3566-99 | Zepbound | 1 SYRINGE in 1 CARTON (0002-3566-99) / 2.4 mL in 1 SYRINGE | 0 | $0 | - | 0 |
| ▶ | 00002-6052-11 | Zepbound | 1 VIAL, MULTI-DOSE in 1 CARTON (0002-6052-11) / 2.4 mL in 1 VIAL, MULTI-DOSE (0002-6052-01) | 0 | $0 | - | 0 |
| ▶ | 00002-6103-11 | Zepbound | 1 VIAL, MULTI-DOSE in 1 CARTON (0002-6103-11) / 2.4 mL in 1 VIAL, MULTI-DOSE (0002-6103-01) | 0 | $0 | - | 0 |
| ▶ | 00002-6210-11 | Zepbound | 1 VIAL, MULTI-DOSE in 1 CARTON (0002-6210-11) / 2.4 mL in 1 VIAL, MULTI-DOSE (0002-6210-01) | 0 | $0 | - | 0 |
| ▶ | 00002-6304-11 | Zepbound | 1 VIAL, MULTI-DOSE in 1 CARTON (0002-6304-11) / 2.4 mL in 1 VIAL, MULTI-DOSE (0002-6304-01) | 0 | $0 | - | 0 |
| ▶ | 00002-6523-11 | Zepbound | 1 VIAL, MULTI-DOSE in 1 CARTON (0002-6523-11) / 2.4 mL in 1 VIAL, MULTI-DOSE (0002-6523-01) | 0 | $0 | - | 0 |
| ▶ | 00002-6612-11 | Zepbound | 1 VIAL, MULTI-DOSE in 1 CARTON (0002-6612-11) / 2.4 mL in 1 VIAL, MULTI-DOSE (0002-6612-01) | 0 | $0 | - | 0 |
Reading the endpoints: the Q4 2025 Wegovy decline is concentrated in North Carolina, whose Medicaid program paused GLP-1 weight-management coverage on Oct 1, 2025 during a budget stalemate and reinstated it Dec 12, 2025. NC Wegovy prescriptions fell from 80,399 (Q3) to 5,578 (Q4) while coverage under the cardiovascular indication continued; 34 jurisdictions still grew that quarter, and Zepbound grew nationally. CMS's most recent quarters also typically revise upward in later releases, and the 2026 file is partial (Q1 only), so endpoint dips are part reporting artifact.
Source: CMS Medicaid State Drug Utilization Data (public domain), extracted by NDC and pulled 2026-07-22; brand→NDC resolution via the openFDA NDC Directory. Suppressed small cells are counted, never imputed; states restate prior quarters, so figures shift slightly between releases. The full panel, methodology, and audit are published as an open dataset (DOI 10.5281/zenodo.21494203, CC BY 4.0); a companion paper is in preparation. See also our open-data page.
Dashboard: openFDA + DailyMed Labels
What's Inside The Pill: Inactive Ingredients At Scale
We parsed the FDA labeling of 51,065 oral drug products and pulled out every declared inactive ingredient (474,126 declarations) to answer questions patients actually ask: how often is lactose in a tablet? If you avoid gelatin or a dye, is there an alternative version of your medicine? This census is published as an open dataset (DOI 10.5281/zenodo.21482069).
Prevalence means the label declares the ingredient; the absence of a declaration is not proof of absence.How Common Is Each Avoidance-Relevant Excipient?
Share of the 50,005 analyzed oral products declaring each ingredient group. Click a bar (or a chip below) to break it down by product type and dose form.
View as table
| Ingredient group | Panel | Products | Prevalence | 95% CI |
|---|---|---|---|---|
| Synthetic color additives | Primary | 19,980 | 39.96% | 39.53-40.39 |
| Lactose | Primary | 19,674 | 39.34% | 38.92-39.77 |
| Propylene glycol | Secondary | 9,980 | 19.96% | 19.61-20.31 |
| Gelatin | Primary | 9,250 | 18.5% | 18.16-18.84 |
| Sucrose | Secondary | 3,944 | 7.89% | 7.65-8.13 |
| Sorbitol | Secondary | 3,744 | 7.49% | 7.26-7.72 |
| Soy-derived | Primary | 1,416 | 2.83% | 2.69-2.98 |
| Aspartame (phenylalanine source) | Secondary | 802 | 1.6% | 1.50-1.72 |
| Benzyl alcohol | Secondary | 300 | 0.6% | 0.54-0.67 |
| Peanut oil | Primary | 72 | 0.14% | 0.11-0.18 |
| Sesame oil | Primary | 15 | 0.03% | 0.02-0.05 |
| Wheat (explicitly declared) | Primary | 6 | 0.01% | 0.01-0.03 |
Wheat (explicitly declared): Counts only ingredients declared as wheat-derived (wheat starch, wheat germ). U.S. oral drugs overwhelmingly use corn or potato starch, so explicit wheat is rare. This figure does NOT include maltodextrin or source-unspecified starches (e.g. sodium starch glycolate), which are usually corn/potato but can rarely be wheat-derived; celiac patients should still confirm the source with the manufacturer.
Where Does It Hide?
Prevalence of the selected ingredient by product type and physical form. The hairline marks its overall prevalence.
View as table (all groups × strata)
| Ingredient group | Overall | Rx | OTC | Generic | Brand | Solid | Liquid | Powder |
|---|---|---|---|---|---|---|---|---|
| Synthetic color additives | 39.96% | 34.82% | 57.48% | 35.91% | 32.74% | 38.87% | 53.82% | 31.78% |
| Lactose | 39.34% | 46.42% | 15.23% | 45.93% | 36.15% | 43.62% | 0.05% | 6.44% |
| Propylene glycol | 19.96% | 17.59% | 28.04% | 18.3% | 12.71% | 17.18% | 54.63% | 1.9% |
| Gelatin | 18.5% | 19.63% | 14.64% | 19.18% | 20.51% | 20.57% | 0% | 0.11% |
| Sucrose | 7.89% | 7% | 10.92% | 6.99% | 8.03% | 5.89% | 20.59% | 47.94% |
| Sorbitol | 7.49% | 2.26% | 25.33% | 2.98% | 6.62% | 3.46% | 51.45% | 8.76% |
| Soy-derived | 2.83% | 2.74% | 3.15% | 2.73% | 2.07% | 3.06% | 0.32% | 3.06% |
| Aspartame (phenylalanine source) | 1.6% | 1.39% | 2.35% | 1.64% | 1.37% | 1.4% | 0.49% | 16.26% |
| Benzyl alcohol | 0.6% | 0.31% | 1.61% | 0.27% | 0.96% | 0.23% | 4.54% | 0.95% |
| Peanut oil | 0.14% | 0.19% | 0% | 0.18% | 0.06% | 0.16% | 0% | 0% |
| Sesame oil | 0.03% | 0.04% | 0% | 0.01% | 0.22% | 0.03% | 0.02% | 0% |
| Wheat (explicitly declared) | 0.01% | 0% | 0.05% | 0% | 0% | 0.01% | 0% | 0.21% |
When There's No Way Around It
Among prescription drugs (same generic name, ≥2 marketed versions) with at least one version declaring the ingredient: the share where every version declares it, so switching products at the pharmacy can't avoid it.
View as table (with example drugs)
| Ingredient group | Affected names | No free option | Locked-in | Examples (all versions declare it) |
|---|---|---|---|---|
| Peanut oil | 2 | 1 | 50% | Progesterone |
| Lactose | 657 | 306 | 46.58% | Buspirone Hydrochloride, Rosuvastatin Calcium, Carvedilol |
| Gelatin | 322 | 150 | 46.58% | Benzonatate, Atomoxetine, Clindamycin Hydrochloride |
| Synthetic color additives | 653 | 158 | 24.2% | Hydralazine Hydrochloride, Clindamycin Hydrochloride, Hydroxyzine Pamoate |
| Sucrose | 200 | 44 | 22% | Erythromycin Ethylsuccinate, Dexlansoprazole, Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate And Amphetamine Aspartate |
| Propylene glycol | 455 | 98 | 21.54% | Pantoprazole, Mexiletine Hydrochloride, Methocarbamol Tablets |
| Benzyl alcohol | 25 | 5 | 20% | Atovaquone, Rimegepant Sulfate, Nortriptyline Hcl |
| Sorbitol | 138 | 24 | 17.39% | Lubiprostone, Bexarotene, Midazolam Hydrochloride |
| Soy-derived | 94 | 15 | 15.96% | Isotretinoin, Progesterone, Ergocalciferol |
| Aspartame (phenylalanine source) | 41 | 4 | 9.76% | Cholestyramine Light, Aripiprazole Orally Disintegrating, Rizatriptan Benzoate Odt |
| Sesame oil | 1 | 0 | 0% | - |
The Dye Count Distribution
Number of distinct synthetic color additives declared per product. 39.96% declare at least one, and a handful declare seven or eight.
View as table
| Distinct dyes declared | Products |
|---|---|
| 0 | 30,025 |
| 1 | 9,683 |
| 2 | 6,381 |
| 3 | 2,464 |
| 4 | 917 |
| 5 | 325 |
| 6 | 164 |
| 7 | 40 |
| 8 | 6 |
Source: our published census of declared inactive ingredients (openFDA NDC Directory export 2026-07-18 + DailyMed Structured Product Labeling; CC BY 4.0, 10.5281/zenodo.21482069). Declared prevalence is a lower bound; quantities are not declared, and declared presence is not a reaction-risk estimate. Talk to your pharmacist about your specific product.
📈 Overall Medicaid Utilization
The whole program in one place: every drug Medicaid filled, aggregated from the CMS State Drug Utilization files by generic — including drugs we don’t have pages for. Prescriptions are actual fills; dollar figures are gross reimbursement before confidential rebates, so treat them as list-price scale, not net program cost. Totals cover Q2 2025 – Q1 2026; the quarterly series runs through Q1 2026.
The League Table
Every drug Medicaid fills, ranked. Toggle the metric — prescription count tells you what people take; gross dollars tells you where the money goes; per-fill shows list-price intensity. The list carries the leaders by each metric, so low-prescription, high-dollar biologics (Stelara, Humira…) surface under Gross $ and $/fill instead of being buried by volume drugs. Drugs we cover link to their pages.
View as table (top 50)
| # | Drug | Rx (Q2 2025 – Q1 2026) | Gross $ | $ / fill |
|---|---|---|---|---|
| 1 | Albuterol | 19,527,981 | $719.2M | $36.83 |
| 2 | Ibuprofen | 13,722,924 | $147.8M | $10.77 |
| 3 | Cetirizine | 12,077,140 | $119.3M | $9.88 |
| 4 | Gabapentin | 11,826,768 | $165.1M | $13.96 |
| 5 | Atorvastatin | 11,527,388 | $123.8M | $10.74 |
| 6 | Amoxicillin | 11,451,458 | $122.3M | $10.68 |
| 7 | Fluticasone | 11,068,970 | $497.3M | $44.93 |
| 8 | Ondansetron | 10,434,600 | $163.8M | $15.70 |
| 9 | Hydroxyzine | 9,012,994 | $106.5M | $11.82 |
| 10 | Sertraline | 8,868,838 | $108.4M | $12.22 |
| 11 | Omeprazole | 8,608,303 | $95.6M | $11.11 |
| 12 | Amphetamine / Amphetamine Aspartate / Dextroamphetamine / Dextroamphetamine Saccharate | 8,366,735 | $354.5M | $42.37 |
| 13 | Amlodipine | 8,001,895 | $80.7M | $10.08 |
| 14 | Metformin | 7,908,177 | $132.7M | $16.78 |
| 15 | Ergocalciferol | 7,906,448 | $64.3M | $8.14 |
| 16 | Trazodone | 7,898,849 | $82.1M | $10.40 |
| 17 | Levothyroxine | 7,786,186 | $126.6M | $16.26 |
| 18 | Acetaminophen | 7,052,202 | $76.2M | $10.81 |
| 19 | Buprenorphine / Naloxone | 6,982,290 | $1.2B | $168.12 |
| 20 | Lisinopril | 6,788,358 | $71M | $10.46 |
| 21 | Famotidine | 6,721,162 | $90.2M | $13.42 |
| 22 | Bupropion | 6,669,702 | $129.8M | $19.47 |
| 23 | Fluoxetine | 6,470,881 | $73.1M | $11.29 |
| 24 | Escitalopram | 6,377,287 | $71.1M | $11.14 |
| 25 | Aspirin | 6,339,210 | $49.9M | $7.87 |
| 26 | Losartan | 5,992,816 | $60M | $10.01 |
| 27 | Metoprolol | 5,974,412 | $63.9M | $10.70 |
| 28 | Clonidine | 5,841,746 | $81.7M | $13.98 |
| 29 | Pantoprazole | 5,788,843 | $65.8M | $11.36 |
| 30 | Quetiapine | 5,743,048 | $73.9M | $12.87 |
| 31 | Triamcinolone | 5,707,239 | $77.9M | $13.65 |
| 32 | Semaglutide | 5,616,018 | $6.3B | $1,116.65 |
| 33 | Methylphenidate | 5,584,708 | $784.1M | $140.40 |
| 34 | Amoxicillin / Clavulanate | 5,453,053 | $82.1M | $15.06 |
| 35 | Prednisone | 5,403,702 | $40.8M | $7.55 |
| 36 | Montelukast | 5,399,653 | $55.2M | $10.23 |
| 37 | Azithromycin | 5,254,152 | $58.3M | $11.10 |
| 38 | Loratadine | 5,204,681 | $44.6M | $8.56 |
| 39 | Buspirone | 5,180,004 | $64.1M | $12.38 |
| 40 | Aripiprazole | 4,917,248 | $1.1B | $218.97 |
| 41 | Diclofenac | 4,613,858 | $112.5M | $24.39 |
| 42 | Acetaminophen / Hydrocodone | 4,550,041 | $66.2M | $14.54 |
| 43 | Cyclobenzaprine | 4,437,147 | $36.3M | $8.19 |
| 44 | Lamotrigine | 4,404,274 | $123.8M | $28.10 |
| 45 | Duloxetine | 4,105,090 | $63.1M | $15.37 |
| 46 | Methadone | 4,056,849 | $25.6M | $6.32 |
| 47 | Guanfacine | 4,036,456 | $65.8M | $16.30 |
| 48 | Lisdexamfetamine | 3,941,773 | $1.2B | $311.15 |
| 49 | Cephalexin | 3,933,834 | $53.1M | $13.50 |
| 50 | Rosuvastatin | 3,856,137 | $44.8M | $11.61 |
State by State
Where the fills happen. Scope to one drug (top 57 available) to see its own geography.
The Quarterly Pulse
National prescriptions per quarter across the whole catalog — pick a drug to overlay its own curve.
Inside a Drug: Product-Level Splits
Our RxNorm pipeline splits a drug’s Medicaid fills across its exact clinical products — each strength & dosage form, brand and generic combined. Pick a drug:
Big in Medicaid, Not on HelloPharmacist (Yet)
The highest-volume drugs we don’t have pages for — in public view because it honestly maps our coverage, and because it’s our to-do list.
- Acetaminophen / Hydrocodone — 4,550,041 Rx
- Docusate — 2,709,192 Rx
- Acetaminophen / Oxycodone — 2,140,047 Rx
- Brompheniramine / Dextromethorphan / Pseudoephedrine — 1,490,229 Rx
- Ethinyl Estradiol / Norgestimate — 1,423,058 Rx
- Nicotine Polacrilex — 730,312 Rx
- Paliperidone Palmitate — 691,208 Rx
- Ethinyl Estradiol / Norethindrone — 649,697 Rx
- Atorvastatin / Film Coated — 594,918 Rx
- Betamethasone / Clotrimazole — 554,662 Rx
- Docusate Sodium Mg / Sennosides Mg — 512,327 Rx
- Isosorbide Mononitrate — 496,404 Rx
- Tiotropium Bromide Inhalation — 436,769 Rx
- Potassium Chloride Extended-release — 364,175 Rx
- Insulin Glargine-yfgn — 361,566 Rx
- Hydrocortisone / Neomycin / Polymyxin B — 343,548 Rx
- Glycopyrrolate — 340,723 Rx
- Olmesartan Medoxomil — 340,022 Rx
- Dextromethorphan Hydrobromide Oral Solution / Promethazine — 295,276 Rx
- Umeclidinium / Vilanterol Trifenatate — 275,927 Rx
- Clindamycin Phosphate Gel Usp — 273,189 Rx
- Electrolytes / Polyethylene Glycol- — 269,460 Rx
- Hydrochlorothiazide Tablets / Lisinopril — 252,231 Rx
- Lidocaine / Prilocaine — 249,236 Rx
- Polyethylene Glycol / Propylene Glycol — 242,674 Rx
Source: CMS Medicaid State Drug Utilization Data, aggregated by FDA generic name across all states, fee-for-service and managed care; small cells are suppressed by CMS before release. Dollars are gross reimbursement before statutory rebates (often large, especially for brands) — net program cost is lower. Dataset refreshes weekly · built 2026-09-17 11:31:06.
More From The Lab
- Everything we publish openly (datasets, DOIs, methods) is indexed on our open data page.
- Declared Inactive Ingredients in U.S. Oral Drug Products: Zenodo dataset (CC BY 4.0).
- Plain-Language FDA Label Glossary (600 terms): Zenodo dataset.
- Consumer Nutrient Guides (21 nutrients): Zenodo dataset.
- The Medicaid GLP-1 panel above is headed for its own open dataset and companion paper; links will land here when they're live.
- Curious what powers the rest of the site? See Data Sources & Update Cadence.